Skip to main content
. 2025 Apr 3;8:100159. doi: 10.1016/j.esmogo.2025.100159

Figure 5.

Figure 5

Sensitivity analyses using the product model. BIL21, Quality of Life Questionnaire Pain and Eating subscales; C2D1, cycle 2 day 1; C2D15, cycle 2 day 15; ITT, intent-to-treat; IVO, ivosidenib; OS, overall survival; PBO, placebo; PFS, progression-free survival; QLQ-C30, Quality of Life Questionnaire Physical Functioning, Pain, and Appetite Loss subscales; RPSFT, rank-preserving structural failure time; SLoS, Scale Loss Score. Benefit criteria: progression-free survival, overall survival, objective response rate, and quality of life (Quality of Life Questionnaire Physical Functioning, Pain, and Appetite Loss subscales). Risk criteria: electrocardiogram QT prolonged, gastrointestinal (diarrhea, vomiting, nausea), fatigue, adverse events leading to treatment discontinuation, and adverse events leading to dose reduction.